Download | - View final version: Engineering the Campylobacter jejuni N-glycan to create an effective chicken vaccine (PDF, 1.7 MiB)
|
---|
DOI | Resolve DOI: https://doi.org/10.1038/srep26511 |
---|
Author | Search for: Nothaft, Harald; Search for: Davis, Brandi; Search for: Lock, Yee Ying; Search for: Perez-munoz, Maria Elisa; Search for: Vinogradov, Evgeny1; Search for: Walter, Jens; Search for: Coros, Colin; Search for: Szymanski, Christine M. |
---|
Affiliation | - National Research Council of Canada. Human Health Therapeutics
|
---|
Format | Text, Article |
---|
Abstract | Campylobacter jejuni is a predominant cause of human gastroenteritis worldwide. Source-attribution studies indicate that chickens are the main reservoir for infection, thus elimination of C. jejuni from poultry would significantly reduce the burden of human disease. We constructed glycoconjugate vaccines combining the conserved C. jejuni N-glycan with a protein carrier, GlycoTag, or fused to the Escherichia coli lipopolysaccharide-core. Vaccination of chickens with the protein-based or E. colidisplayed glycoconjugate showed up to 10-log reduction in C. jejuni colonization and induced N-glycanspecific IgY responses. Moreover, the live E. coli vaccine was cleared prior to C. jejuni challenge and no selection for resistant campylobacter variants was observed. Analyses of the chicken gut communities revealed that the live vaccine did not alter the composition or complexity of the microbiome, thus representing an effective and low-cost strategy to reduce C. jejuni in chickens and its subsequent entry into the food chain. |
---|
Publication date | 2016-05-25 |
---|
In | |
---|
Language | English |
---|
Peer reviewed | Yes |
---|
NPARC number | 23000027 |
---|
Export citation | Export as RIS |
---|
Report a correction | Report a correction (opens in a new tab) |
---|
Record identifier | a2604660-581b-4ea9-a388-6d722e601592 |
---|
Record created | 2016-05-30 |
---|
Record modified | 2020-06-02 |
---|